nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—CYP3A4—bone cancer	0.506	1	CbGaD
Mifepristone—ABCC1—Epirubicin—bone cancer	0.144	0.372	CbGbCtD
Mifepristone—ABCC1—Doxorubicin—bone cancer	0.0764	0.198	CbGbCtD
Mifepristone—ABCC1—Methotrexate—bone cancer	0.074	0.192	CbGbCtD
Mifepristone—ABCB1—Cisplatin—bone cancer	0.0275	0.0712	CbGbCtD
Mifepristone—ABCB1—Doxorubicin—bone cancer	0.0184	0.0477	CbGbCtD
Mifepristone—ABCB1—Methotrexate—bone cancer	0.0178	0.0462	CbGbCtD
Mifepristone—CYP2D6—Doxorubicin—bone cancer	0.0174	0.045	CbGbCtD
Mifepristone—CYP3A4—Doxorubicin—bone cancer	0.011	0.0286	CbGbCtD
Mifepristone—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00218	0.0357	CbGpPWpGaD
Mifepristone—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00194	0.0318	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.00178	0.0291	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptors—NR1I2—bone cancer	0.00168	0.0276	CbGpPWpGaD
Mifepristone—ABCC1—Irinotecan Pathway—CYP3A4—bone cancer	0.00143	0.0234	CbGpPWpGaD
Mifepristone—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0014	0.023	CbGpPWpGaD
Mifepristone—PGR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00133	0.0218	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptors—NR1I2—bone cancer	0.00128	0.021	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.00123	0.0201	CbGpPWpGaD
Mifepristone—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.00114	0.0187	CbGpPWpGaD
Mifepristone—Musculoskeletal chest pain—Epirubicin—bone cancer	0.00107	0.0229	CcSEcCtD
Mifepristone—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00106	0.0174	CbGpPWpGaD
Mifepristone—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.00103	0.0169	CbGpPWpGaD
Mifepristone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.00102	0.0166	CbGpPWpGaD
Mifepristone—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00101	0.0166	CbGpPWpGaD
Mifepristone—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.001	0.0164	CbGpPWpGaD
Mifepristone—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000997	0.0163	CbGpPWpGaD
Mifepristone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000996	0.0163	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000994	0.0163	CbGpPWpGaD
Mifepristone—Musculoskeletal chest pain—Doxorubicin—bone cancer	0.000994	0.0212	CcSEcCtD
Mifepristone—Infection—Carboplatin—bone cancer	0.00098	0.0209	CcSEcCtD
Mifepristone—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.000974	0.016	CbGpPWpGaD
Mifepristone—Erythema nodosum—Epirubicin—bone cancer	0.000963	0.0205	CcSEcCtD
Mifepristone—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000936	0.0153	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00093	0.0152	CbGpPWpGaD
Mifepristone—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.0009	0.0147	CbGpPWpGaD
Mifepristone—Erythema nodosum—Doxorubicin—bone cancer	0.000891	0.019	CcSEcCtD
Mifepristone—Pain—Carboplatin—bone cancer	0.000843	0.018	CcSEcCtD
Mifepristone—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000835	0.0137	CbGpPWpGaD
Mifepristone—Body temperature increased—Carboplatin—bone cancer	0.00078	0.0166	CcSEcCtD
Mifepristone—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00077	0.0126	CbGpPWpGaD
Mifepristone—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000705	0.0116	CbGpPWpGaD
Mifepristone—PGR—Ovarian Infertility Genes—CDK4—bone cancer	0.0007	0.0115	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—ZNF77—bone cancer	0.000679	0.0111	CbGpPWpGaD
Mifepristone—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000677	0.0111	CbGpPWpGaD
Mifepristone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000652	0.0107	CbGpPWpGaD
Mifepristone—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000651	0.0107	CbGpPWpGaD
Mifepristone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000613	0.01	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000604	0.00989	CbGpPWpGaD
Mifepristone—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000582	0.00953	CbGpPWpGaD
Mifepristone—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000575	0.00943	CbGpPWpGaD
Mifepristone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000572	0.00937	CbGpPWpGaD
Mifepristone—Vaginal haemorrhage—Epirubicin—bone cancer	0.000563	0.012	CcSEcCtD
Mifepristone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.000543	0.0089	CbGpPWpGaD
Mifepristone—Hypokalaemia—Cisplatin—bone cancer	0.000536	0.0114	CcSEcCtD
Mifepristone—Breast disorder—Cisplatin—bone cancer	0.000532	0.0113	CcSEcCtD
Mifepristone—Cramp muscle—Cisplatin—bone cancer	0.00053	0.0113	CcSEcCtD
Mifepristone—Nasopharyngitis—Cisplatin—bone cancer	0.000526	0.0112	CcSEcCtD
Mifepristone—Vaginal haemorrhage—Doxorubicin—bone cancer	0.000521	0.0111	CcSEcCtD
Mifepristone—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.000518	0.00848	CbGpPWpGaD
Mifepristone—ABCC1—S1P1 pathway—PTGS2—bone cancer	0.000496	0.00812	CbGpPWpGaD
Mifepristone—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000481	0.00788	CbGpPWpGaD
Mifepristone—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000465	0.00761	CbGpPWpGaD
Mifepristone—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000463	0.00758	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000429	0.00703	CbGpPWpGaD
Mifepristone—Connective tissue disorder—Cisplatin—bone cancer	0.0004	0.00853	CcSEcCtD
Mifepristone—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.000393	0.00643	CbGpPWpGaD
Mifepristone—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.000392	0.00643	CbGpPWpGaD
Mifepristone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000391	0.0064	CbGpPWpGaD
Mifepristone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000389	0.00637	CbGpPWpGaD
Mifepristone—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000384	0.00629	CbGpPWpGaD
Mifepristone—Rash maculo-papular—Epirubicin—bone cancer	0.000378	0.00807	CcSEcCtD
Mifepristone—Mediastinal disorder—Cisplatin—bone cancer	0.000367	0.00782	CcSEcCtD
Mifepristone—Malnutrition—Cisplatin—bone cancer	0.000354	0.00756	CcSEcCtD
Mifepristone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000352	0.00577	CbGpPWpGaD
Mifepristone—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000351	0.00574	CbGpPWpGaD
Mifepristone—Rash maculo-papular—Doxorubicin—bone cancer	0.00035	0.00747	CcSEcCtD
Mifepristone—Dermatitis exfoliative—Methotrexate—bone cancer	0.000342	0.0073	CcSEcCtD
Mifepristone—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.000341	0.00559	CbGpPWpGaD
Mifepristone—Muscle spasms—Cisplatin—bone cancer	0.000341	0.00727	CcSEcCtD
Mifepristone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000334	0.00547	CbGpPWpGaD
Mifepristone—Ill-defined disorder—Cisplatin—bone cancer	0.000329	0.00701	CcSEcCtD
Mifepristone—PGR—Gene Expression—ZNF77—bone cancer	0.000327	0.00536	CbGpPWpGaD
Mifepristone—Hot flush—Epirubicin—bone cancer	0.000323	0.00689	CcSEcCtD
Mifepristone—Dermatitis exfoliative—Epirubicin—bone cancer	0.00032	0.00683	CcSEcCtD
Mifepristone—Menopausal symptoms—Epirubicin—bone cancer	0.00032	0.00683	CcSEcCtD
Mifepristone—Malaise—Cisplatin—bone cancer	0.00032	0.00682	CcSEcCtD
Mifepristone—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000315	0.00516	CbGpPWpGaD
Mifepristone—Hypoglycaemia—Epirubicin—bone cancer	0.00031	0.0066	CcSEcCtD
Mifepristone—Pain in extremity—Epirubicin—bone cancer	0.000302	0.00644	CcSEcCtD
Mifepristone—Myalgia—Cisplatin—bone cancer	0.000302	0.00643	CcSEcCtD
Mifepristone—Anxiety—Cisplatin—bone cancer	0.000301	0.00641	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.0003	0.00639	CcSEcCtD
Mifepristone—Hot flush—Doxorubicin—bone cancer	0.000299	0.00637	CcSEcCtD
Mifepristone—Discomfort—Cisplatin—bone cancer	0.000298	0.00636	CcSEcCtD
Mifepristone—Menopausal symptoms—Doxorubicin—bone cancer	0.000296	0.00632	CcSEcCtD
Mifepristone—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000296	0.00632	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000292	0.00479	CbGpPWpGaD
Mifepristone—Breast disorder—Methotrexate—bone cancer	0.000292	0.00622	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000291	0.0062	CcSEcCtD
Mifepristone—Oedema—Cisplatin—bone cancer	0.000289	0.00617	CcSEcCtD
Mifepristone—Infection—Cisplatin—bone cancer	0.000287	0.00613	CcSEcCtD
Mifepristone—Hypoglycaemia—Doxorubicin—bone cancer	0.000287	0.00611	CcSEcCtD
Mifepristone—Nervous system disorder—Cisplatin—bone cancer	0.000284	0.00605	CcSEcCtD
Mifepristone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000281	0.0046	CbGpPWpGaD
Mifepristone—Skin disorder—Cisplatin—bone cancer	0.000281	0.00599	CcSEcCtD
Mifepristone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000281	0.0046	CbGpPWpGaD
Mifepristone—Pain in extremity—Doxorubicin—bone cancer	0.00028	0.00596	CcSEcCtD
Mifepristone—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000277	0.00454	CbGpPWpGaD
Mifepristone—Anorexia—Cisplatin—bone cancer	0.000276	0.00588	CcSEcCtD
Mifepristone—Hypokalaemia—Epirubicin—bone cancer	0.000275	0.00587	CcSEcCtD
Mifepristone—Breast disorder—Epirubicin—bone cancer	0.000273	0.00582	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000272	0.0058	CcSEcCtD
Mifepristone—Hypotension—Cisplatin—bone cancer	0.00027	0.00576	CcSEcCtD
Mifepristone—Nasopharyngitis—Epirubicin—bone cancer	0.00027	0.00576	CcSEcCtD
Mifepristone—Muscular weakness—Epirubicin—bone cancer	0.000267	0.00568	CcSEcCtD
Mifepristone—AR—FOXA1 transcription factor network—JUN—bone cancer	0.000266	0.00436	CbGpPWpGaD
Mifepristone—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000264	0.00433	CbGpPWpGaD
Mifepristone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000264	0.00562	CcSEcCtD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000259	0.00424	CbGpPWpGaD
Mifepristone—Dyspnoea—Cisplatin—bone cancer	0.000258	0.0055	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000255	0.00418	CbGpPWpGaD
Mifepristone—Hypokalaemia—Doxorubicin—bone cancer	0.000255	0.00543	CcSEcCtD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000254	0.00416	CbGpPWpGaD
Mifepristone—Breast disorder—Doxorubicin—bone cancer	0.000253	0.00539	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000252	0.00537	CcSEcCtD
Mifepristone—Decreased appetite—Cisplatin—bone cancer	0.000251	0.00536	CcSEcCtD
Mifepristone—Nasopharyngitis—Doxorubicin—bone cancer	0.00025	0.00533	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Cisplatin—bone cancer	0.00025	0.00533	CcSEcCtD
Mifepristone—AR—Gene Expression—ZNF77—bone cancer	0.000249	0.00408	CbGpPWpGaD
Mifepristone—Infestation NOS—Methotrexate—bone cancer	0.000249	0.00531	CcSEcCtD
Mifepristone—Infestation—Methotrexate—bone cancer	0.000249	0.00531	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000249	0.00407	CbGpPWpGaD
Mifepristone—Pain—Cisplatin—bone cancer	0.000247	0.00527	CcSEcCtD
Mifepristone—Muscular weakness—Doxorubicin—bone cancer	0.000247	0.00526	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000245	0.00402	CbGpPWpGaD
Mifepristone—Feeling abnormal—Cisplatin—bone cancer	0.000238	0.00508	CcSEcCtD
Mifepristone—Infestation NOS—Epirubicin—bone cancer	0.000233	0.00497	CcSEcCtD
Mifepristone—Infestation—Epirubicin—bone cancer	0.000233	0.00497	CcSEcCtD
Mifepristone—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.00023	0.00377	CbGpPWpGaD
Mifepristone—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.00023	0.00376	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	0.000229	0.00375	CbGpPWpGaD
Mifepristone—Body temperature increased—Cisplatin—bone cancer	0.000229	0.00488	CcSEcCtD
Mifepristone—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000229	0.00374	CbGpPWpGaD
Mifepristone—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000228	0.00373	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000226	0.00371	CbGpPWpGaD
Mifepristone—Haemoglobin—Methotrexate—bone cancer	0.000225	0.00479	CcSEcCtD
Mifepristone—Haemorrhage—Methotrexate—bone cancer	0.000223	0.00476	CcSEcCtD
Mifepristone—Sinusitis—Epirubicin—bone cancer	0.000219	0.00466	CcSEcCtD
Mifepristone—Infestation NOS—Doxorubicin—bone cancer	0.000216	0.0046	CcSEcCtD
Mifepristone—Infestation—Doxorubicin—bone cancer	0.000216	0.0046	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000214	0.0035	CbGpPWpGaD
Mifepristone—Hypersensitivity—Cisplatin—bone cancer	0.000213	0.00454	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000213	0.00348	CbGpPWpGaD
Mifepristone—Haemoglobin—Epirubicin—bone cancer	0.00021	0.00448	CcSEcCtD
Mifepristone—Haemorrhage—Epirubicin—bone cancer	0.000209	0.00446	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000208	0.00341	CbGpPWpGaD
Mifepristone—Asthenia—Cisplatin—bone cancer	0.000208	0.00443	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000206	0.00338	CbGpPWpGaD
Mifepristone—Oedema peripheral—Epirubicin—bone cancer	0.000206	0.00439	CcSEcCtD
Mifepristone—Connective tissue disorder—Epirubicin—bone cancer	0.000205	0.00438	CcSEcCtD
Mifepristone—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.000205	0.00335	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000203	0.00333	CbGpPWpGaD
Mifepristone—Angiopathy—Methotrexate—bone cancer	0.000203	0.00432	CcSEcCtD
Mifepristone—Sinusitis—Doxorubicin—bone cancer	0.000202	0.00431	CcSEcCtD
Mifepristone—Mediastinal disorder—Methotrexate—bone cancer	0.000201	0.00429	CcSEcCtD
Mifepristone—Chills—Methotrexate—bone cancer	0.0002	0.00427	CcSEcCtD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.0002	0.00328	CbGpPWpGaD
Mifepristone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0002	0.00327	CbGpPWpGaD
Mifepristone—Diarrhoea—Cisplatin—bone cancer	0.000198	0.00422	CcSEcCtD
Mifepristone—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000197	0.00323	CbGpPWpGaD
Mifepristone—Mental disorder—Methotrexate—bone cancer	0.000196	0.00417	CcSEcCtD
Mifepristone—Malnutrition—Methotrexate—bone cancer	0.000195	0.00415	CcSEcCtD
Mifepristone—Haemoglobin—Doxorubicin—bone cancer	0.000194	0.00415	CcSEcCtD
Mifepristone—Haemorrhage—Doxorubicin—bone cancer	0.000193	0.00413	CcSEcCtD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000193	0.00315	CbGpPWpGaD
Mifepristone—Oedema peripheral—Doxorubicin—bone cancer	0.000191	0.00406	CcSEcCtD
Mifepristone—Connective tissue disorder—Doxorubicin—bone cancer	0.00019	0.00405	CcSEcCtD
Mifepristone—Angiopathy—Epirubicin—bone cancer	0.00019	0.00405	CcSEcCtD
Mifepristone—PGR—Signaling by ERBB4—KIT—bone cancer	0.000189	0.0031	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—ZNF77—bone cancer	0.000189	0.0031	CbGpPWpGaD
Mifepristone—Mediastinal disorder—Epirubicin—bone cancer	0.000188	0.00402	CcSEcCtD
Mifepristone—Back pain—Methotrexate—bone cancer	0.000188	0.00401	CcSEcCtD
Mifepristone—Chills—Epirubicin—bone cancer	0.000188	0.004	CcSEcCtD
Mifepristone—Vomiting—Cisplatin—bone cancer	0.000184	0.00392	CcSEcCtD
Mifepristone—Mental disorder—Epirubicin—bone cancer	0.000183	0.00391	CcSEcCtD
Mifepristone—Rash—Cisplatin—bone cancer	0.000182	0.00389	CcSEcCtD
Mifepristone—Dermatitis—Cisplatin—bone cancer	0.000182	0.00389	CcSEcCtD
Mifepristone—Malnutrition—Epirubicin—bone cancer	0.000182	0.00388	CcSEcCtD
Mifepristone—Ill-defined disorder—Methotrexate—bone cancer	0.00018	0.00385	CcSEcCtD
Mifepristone—Back pain—Epirubicin—bone cancer	0.000176	0.00375	CcSEcCtD
Mifepristone—Angiopathy—Doxorubicin—bone cancer	0.000176	0.00374	CcSEcCtD
Mifepristone—Malaise—Methotrexate—bone cancer	0.000175	0.00374	CcSEcCtD
Mifepristone—AR—Generic Transcription Pathway—NR1I2—bone cancer	0.000175	0.00287	CbGpPWpGaD
Mifepristone—Muscle spasms—Epirubicin—bone cancer	0.000175	0.00373	CcSEcCtD
Mifepristone—AR—Androgen receptor signaling pathway—MDM2—bone cancer	0.000174	0.00286	CbGpPWpGaD
Mifepristone—Mediastinal disorder—Doxorubicin—bone cancer	0.000174	0.00372	CcSEcCtD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	0.000174	0.00285	CbGpPWpGaD
Mifepristone—Chills—Doxorubicin—bone cancer	0.000174	0.0037	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000172	0.00282	CbGpPWpGaD
Mifepristone—Nausea—Cisplatin—bone cancer	0.000172	0.00366	CcSEcCtD
Mifepristone—Mental disorder—Doxorubicin—bone cancer	0.00017	0.00361	CcSEcCtD
Mifepristone—Ill-defined disorder—Epirubicin—bone cancer	0.000169	0.0036	CcSEcCtD
Mifepristone—Malnutrition—Doxorubicin—bone cancer	0.000168	0.00359	CcSEcCtD
Mifepristone—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000167	0.00274	CbGpPWpGaD
Mifepristone—Myalgia—Methotrexate—bone cancer	0.000166	0.00353	CcSEcCtD
Mifepristone—Arthralgia—Methotrexate—bone cancer	0.000166	0.00353	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000165	0.00271	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000165	0.00271	CbGpPWpGaD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000164	0.00351	CcSEcCtD
Mifepristone—Malaise—Epirubicin—bone cancer	0.000164	0.0035	CcSEcCtD
Mifepristone—Discomfort—Methotrexate—bone cancer	0.000164	0.00349	CcSEcCtD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000164	0.00268	CbGpPWpGaD
Mifepristone—Back pain—Doxorubicin—bone cancer	0.000163	0.00347	CcSEcCtD
Mifepristone—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000162	0.00265	CbGpPWpGaD
Mifepristone—Muscle spasms—Doxorubicin—bone cancer	0.000162	0.00345	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000161	0.00263	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—FUS—bone cancer	0.00016	0.00262	CbGpPWpGaD
Mifepristone—Infection—Methotrexate—bone cancer	0.000158	0.00336	CcSEcCtD
Mifepristone—Hypertension—Epirubicin—bone cancer	0.000157	0.00335	CcSEcCtD
Mifepristone—Ill-defined disorder—Doxorubicin—bone cancer	0.000156	0.00333	CcSEcCtD
Mifepristone—Nervous system disorder—Methotrexate—bone cancer	0.000156	0.00332	CcSEcCtD
Mifepristone—Arthralgia—Epirubicin—bone cancer	0.000155	0.0033	CcSEcCtD
Mifepristone—Myalgia—Epirubicin—bone cancer	0.000155	0.0033	CcSEcCtD
Mifepristone—Anxiety—Epirubicin—bone cancer	0.000154	0.00329	CcSEcCtD
Mifepristone—Skin disorder—Methotrexate—bone cancer	0.000154	0.00329	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000154	0.00253	CbGpPWpGaD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000154	0.00328	CcSEcCtD
Mifepristone—Discomfort—Epirubicin—bone cancer	0.000153	0.00326	CcSEcCtD
Mifepristone—Malaise—Doxorubicin—bone cancer	0.000152	0.00324	CcSEcCtD
Mifepristone—AR—Androgen receptor signaling pathway—JUN—bone cancer	0.000152	0.00248	CbGpPWpGaD
Mifepristone—Dry mouth—Epirubicin—bone cancer	0.000152	0.00323	CcSEcCtD
Mifepristone—Anorexia—Methotrexate—bone cancer	0.000151	0.00323	CcSEcCtD
Mifepristone—PGR—Signaling by ERBB4—MDM2—bone cancer	0.000149	0.00244	CbGpPWpGaD
Mifepristone—Oedema—Epirubicin—bone cancer	0.000149	0.00317	CcSEcCtD
Mifepristone—Hypotension—Methotrexate—bone cancer	0.000148	0.00316	CcSEcCtD
Mifepristone—Infection—Epirubicin—bone cancer	0.000148	0.00315	CcSEcCtD
Mifepristone—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000147	0.00241	CbGpPWpGaD
Mifepristone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000147	0.0024	CbGpPWpGaD
Mifepristone—Nervous system disorder—Epirubicin—bone cancer	0.000146	0.00311	CcSEcCtD
Mifepristone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000146	0.00238	CbGpPWpGaD
Mifepristone—Hypertension—Doxorubicin—bone cancer	0.000145	0.0031	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000145	0.00308	CcSEcCtD
Mifepristone—Skin disorder—Epirubicin—bone cancer	0.000144	0.00308	CcSEcCtD
Mifepristone—Insomnia—Methotrexate—bone cancer	0.000144	0.00306	CcSEcCtD
Mifepristone—Arthralgia—Doxorubicin—bone cancer	0.000143	0.00306	CcSEcCtD
Mifepristone—Myalgia—Doxorubicin—bone cancer	0.000143	0.00306	CcSEcCtD
Mifepristone—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000143	0.00235	CbGpPWpGaD
Mifepristone—Anxiety—Doxorubicin—bone cancer	0.000143	0.00305	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000142	0.00304	CcSEcCtD
Mifepristone—Discomfort—Doxorubicin—bone cancer	0.000142	0.00302	CcSEcCtD
Mifepristone—Anorexia—Epirubicin—bone cancer	0.000142	0.00302	CcSEcCtD
Mifepristone—Dyspnoea—Methotrexate—bone cancer	0.000142	0.00302	CcSEcCtD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.000141	0.00232	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000141	0.00231	CbGpPWpGaD
Mifepristone—Somnolence—Methotrexate—bone cancer	0.000141	0.00301	CcSEcCtD
Mifepristone—Dry mouth—Doxorubicin—bone cancer	0.00014	0.00299	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—JUN—bone cancer	0.000139	0.00228	CbGpPWpGaD
Mifepristone—Hypotension—Epirubicin—bone cancer	0.000139	0.00296	CcSEcCtD
Mifepristone—Decreased appetite—Methotrexate—bone cancer	0.000138	0.00294	CcSEcCtD
Mifepristone—Oedema—Doxorubicin—bone cancer	0.000137	0.00293	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000137	0.00292	CcSEcCtD
Mifepristone—Fatigue—Methotrexate—bone cancer	0.000137	0.00292	CcSEcCtD
Mifepristone—Infection—Doxorubicin—bone cancer	0.000137	0.00291	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000136	0.00223	CbGpPWpGaD
Mifepristone—Pain—Methotrexate—bone cancer	0.000136	0.00289	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	0.000136	0.00222	CbGpPWpGaD
Mifepristone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000135	0.00289	CcSEcCtD
Mifepristone—Nervous system disorder—Doxorubicin—bone cancer	0.000135	0.00287	CcSEcCtD
Mifepristone—Insomnia—Epirubicin—bone cancer	0.000134	0.00286	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000134	0.0022	CbGpPWpGaD
Mifepristone—Skin disorder—Doxorubicin—bone cancer	0.000134	0.00285	CcSEcCtD
Mifepristone—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	0.000133	0.00218	CbGpPWpGaD
Mifepristone—Dyspnoea—Epirubicin—bone cancer	0.000132	0.00282	CcSEcCtD
Mifepristone—Somnolence—Epirubicin—bone cancer	0.000132	0.00282	CcSEcCtD
Mifepristone—Anorexia—Doxorubicin—bone cancer	0.000131	0.00279	CcSEcCtD
Mifepristone—Feeling abnormal—Methotrexate—bone cancer	0.000131	0.00279	CcSEcCtD
Mifepristone—Gastrointestinal pain—Methotrexate—bone cancer	0.00013	0.00277	CcSEcCtD
Mifepristone—Decreased appetite—Epirubicin—bone cancer	0.000129	0.00275	CcSEcCtD
Mifepristone—Hypotension—Doxorubicin—bone cancer	0.000128	0.00274	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000128	0.00273	CcSEcCtD
Mifepristone—Fatigue—Epirubicin—bone cancer	0.000128	0.00273	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000128	0.00209	CbGpPWpGaD
Mifepristone—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000127	0.00208	CbGpPWpGaD
Mifepristone—Pain—Epirubicin—bone cancer	0.000127	0.00271	CcSEcCtD
Mifepristone—Constipation—Epirubicin—bone cancer	0.000127	0.00271	CcSEcCtD
Mifepristone—Urticaria—Methotrexate—bone cancer	0.000126	0.00269	CcSEcCtD
Mifepristone—Abdominal pain—Methotrexate—bone cancer	0.000125	0.00268	CcSEcCtD
Mifepristone—Body temperature increased—Methotrexate—bone cancer	0.000125	0.00268	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000125	0.00267	CcSEcCtD
Mifepristone—Insomnia—Doxorubicin—bone cancer	0.000124	0.00265	CcSEcCtD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000124	0.00203	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	0.000123	0.00201	CbGpPWpGaD
Mifepristone—Dyspnoea—Doxorubicin—bone cancer	0.000123	0.00261	CcSEcCtD
Mifepristone—Feeling abnormal—Epirubicin—bone cancer	0.000122	0.00261	CcSEcCtD
Mifepristone—Somnolence—Doxorubicin—bone cancer	0.000122	0.00261	CcSEcCtD
Mifepristone—AR—Gene Expression—FUS—bone cancer	0.000122	0.00199	CbGpPWpGaD
Mifepristone—Gastrointestinal pain—Epirubicin—bone cancer	0.000121	0.00259	CcSEcCtD
Mifepristone—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000121	0.00198	CbGpPWpGaD
Mifepristone—Decreased appetite—Doxorubicin—bone cancer	0.000119	0.00255	CcSEcCtD
Mifepristone—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000119	0.00196	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—EGFR—bone cancer	0.000119	0.00195	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000119	0.00195	CbGpPWpGaD
Mifepristone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000119	0.00253	CcSEcCtD
Mifepristone—Fatigue—Doxorubicin—bone cancer	0.000119	0.00253	CcSEcCtD
Mifepristone—Urticaria—Epirubicin—bone cancer	0.000118	0.00252	CcSEcCtD
Mifepristone—Constipation—Doxorubicin—bone cancer	0.000118	0.00251	CcSEcCtD
Mifepristone—Pain—Doxorubicin—bone cancer	0.000118	0.00251	CcSEcCtD
Mifepristone—Body temperature increased—Epirubicin—bone cancer	0.000117	0.0025	CcSEcCtD
Mifepristone—Abdominal pain—Epirubicin—bone cancer	0.000117	0.0025	CcSEcCtD
Mifepristone—Hypersensitivity—Methotrexate—bone cancer	0.000117	0.00249	CcSEcCtD
Mifepristone—ABCC1—Metabolism—NDUFA12—bone cancer	0.000115	0.00189	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—RB1—bone cancer	0.000115	0.00188	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000114	0.00187	CbGpPWpGaD
Mifepristone—Asthenia—Methotrexate—bone cancer	0.000114	0.00243	CcSEcCtD
Mifepristone—Feeling abnormal—Doxorubicin—bone cancer	0.000113	0.00242	CcSEcCtD
Mifepristone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000112	0.0024	CcSEcCtD
Mifepristone—Pruritus—Methotrexate—bone cancer	0.000112	0.00239	CcSEcCtD
Mifepristone—PGR—Gene Expression—NR1I2—bone cancer	0.000111	0.00181	CbGpPWpGaD
Mifepristone—Hypersensitivity—Epirubicin—bone cancer	0.000109	0.00233	CcSEcCtD
Mifepristone—Urticaria—Doxorubicin—bone cancer	0.000109	0.00233	CcSEcCtD
Mifepristone—Abdominal pain—Doxorubicin—bone cancer	0.000109	0.00232	CcSEcCtD
Mifepristone—Body temperature increased—Doxorubicin—bone cancer	0.000109	0.00232	CcSEcCtD
Mifepristone—Diarrhoea—Methotrexate—bone cancer	0.000109	0.00232	CcSEcCtD
Mifepristone—Asthenia—Epirubicin—bone cancer	0.000107	0.00227	CcSEcCtD
Mifepristone—Pruritus—Epirubicin—bone cancer	0.000105	0.00224	CcSEcCtD
Mifepristone—Dizziness—Methotrexate—bone cancer	0.000105	0.00224	CcSEcCtD
Mifepristone—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000104	0.0017	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000102	0.00167	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—EGFR—bone cancer	0.000102	0.00167	CbGpPWpGaD
Mifepristone—Diarrhoea—Epirubicin—bone cancer	0.000102	0.00217	CcSEcCtD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000101	0.00166	CbGpPWpGaD
Mifepristone—Hypersensitivity—Doxorubicin—bone cancer	0.000101	0.00216	CcSEcCtD
Mifepristone—Vomiting—Methotrexate—bone cancer	0.000101	0.00215	CcSEcCtD
Mifepristone—CYP3A7—Metabolism—NDUFA12—bone cancer	0.0001	0.00164	CbGpPWpGaD
Mifepristone—Rash—Methotrexate—bone cancer	0.0001	0.00213	CcSEcCtD
Mifepristone—Dermatitis—Methotrexate—bone cancer	0.0001	0.00213	CcSEcCtD
Mifepristone—Headache—Methotrexate—bone cancer	9.94e-05	0.00212	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	9.94e-05	0.00163	CbGpPWpGaD
Mifepristone—Asthenia—Doxorubicin—bone cancer	9.86e-05	0.0021	CcSEcCtD
Mifepristone—Dizziness—Epirubicin—bone cancer	9.82e-05	0.00209	CcSEcCtD
Mifepristone—Pruritus—Doxorubicin—bone cancer	9.73e-05	0.00207	CcSEcCtD
Mifepristone—AR—SIDS Susceptibility Pathways—JUN—bone cancer	9.68e-05	0.00159	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—NT5C3A—bone cancer	9.54e-05	0.00156	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	9.47e-05	0.00155	CbGpPWpGaD
Mifepristone—Vomiting—Epirubicin—bone cancer	9.45e-05	0.00201	CcSEcCtD
Mifepristone—Nausea—Methotrexate—bone cancer	9.43e-05	0.00201	CcSEcCtD
Mifepristone—Diarrhoea—Doxorubicin—bone cancer	9.41e-05	0.00201	CcSEcCtD
Mifepristone—Rash—Epirubicin—bone cancer	9.37e-05	0.002	CcSEcCtD
Mifepristone—Dermatitis—Epirubicin—bone cancer	9.36e-05	0.002	CcSEcCtD
Mifepristone—Headache—Epirubicin—bone cancer	9.31e-05	0.00198	CcSEcCtD
Mifepristone—NR3C1—Gene Expression—FUS—bone cancer	9.23e-05	0.00151	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	9.22e-05	0.00151	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—TP53—bone cancer	9.2e-05	0.00151	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	9.13e-05	0.0015	CbGpPWpGaD
Mifepristone—Dizziness—Doxorubicin—bone cancer	9.09e-05	0.00194	CcSEcCtD
Mifepristone—Nausea—Epirubicin—bone cancer	8.82e-05	0.00188	CcSEcCtD
Mifepristone—Vomiting—Doxorubicin—bone cancer	8.74e-05	0.00186	CcSEcCtD
Mifepristone—Rash—Doxorubicin—bone cancer	8.67e-05	0.00185	CcSEcCtD
Mifepristone—Dermatitis—Doxorubicin—bone cancer	8.66e-05	0.00185	CcSEcCtD
Mifepristone—Headache—Doxorubicin—bone cancer	8.61e-05	0.00184	CcSEcCtD
Mifepristone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.61e-05	0.00141	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	8.49e-05	0.00139	CbGpPWpGaD
Mifepristone—AR—Gene Expression—NR1I2—bone cancer	8.44e-05	0.00138	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	8.4e-05	0.00138	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—NT5C3A—bone cancer	8.32e-05	0.00136	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—GRM4—bone cancer	8.3e-05	0.00136	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—RGS1—bone cancer	8.3e-05	0.00136	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	8.28e-05	0.00136	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	8.23e-05	0.00135	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—EIF2S1—bone cancer	8.18e-05	0.00134	CbGpPWpGaD
Mifepristone—Nausea—Doxorubicin—bone cancer	8.16e-05	0.00174	CcSEcCtD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	8.11e-05	0.00133	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	7.85e-05	0.00129	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	7.81e-05	0.00128	CbGpPWpGaD
Mifepristone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.43e-05	0.00122	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—GSTP1—bone cancer	7.36e-05	0.00121	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	7.34e-05	0.0012	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	7.26e-05	0.00119	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—NDUFA12—bone cancer	7.26e-05	0.00119	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—GRM1—bone cancer	7.2e-05	0.00118	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—EZH2—bone cancer	7.1e-05	0.00116	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.02e-05	0.00115	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7e-05	0.00115	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	6.56e-05	0.00107	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.47e-05	0.00106	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—NR1I2—bone cancer	6.4e-05	0.00105	CbGpPWpGaD
Mifepristone—AR—Gene Expression—EIF2S1—bone cancer	6.23e-05	0.00102	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.04e-05	0.00099	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—NT5C3A—bone cancer	6.01e-05	0.000985	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—NDUFA12—bone cancer	5.47e-05	0.000897	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.43e-05	0.00089	CbGpPWpGaD
Mifepristone—AR—Gene Expression—EZH2—bone cancer	5.41e-05	0.000887	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.21e-05	0.000853	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—NDUFA12—bone cancer	5.16e-05	0.000845	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—SMO—bone cancer	5.07e-05	0.000831	CbGpPWpGaD
Mifepristone—ABCC1—Disease—ENO2—bone cancer	4.99e-05	0.000817	CbGpPWpGaD
Mifepristone—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.81e-05	0.000788	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.75e-05	0.000778	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—EIF2S1—bone cancer	4.73e-05	0.000774	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—GNA11—bone cancer	4.64e-05	0.00076	CbGpPWpGaD
Mifepristone—ABCC1—Disease—DHFR—bone cancer	4.63e-05	0.000758	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—NT5C3A—bone cancer	4.54e-05	0.000743	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—ATF1—bone cancer	4.31e-05	0.000707	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—NT5C3A—bone cancer	4.27e-05	0.0007	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—IL3—bone cancer	4.21e-05	0.000689	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—ENO2—bone cancer	4.18e-05	0.000684	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—EZH2—bone cancer	4.11e-05	0.000673	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—DHFR—bone cancer	3.87e-05	0.000635	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.86e-05	0.000632	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.72e-05	0.00061	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—ENO2—bone cancer	3.64e-05	0.000597	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—GNA11—bone cancer	3.62e-05	0.000593	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TGFBR2—bone cancer	3.6e-05	0.000589	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—IGF1R—bone cancer	3.38e-05	0.000554	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—DHFR—bone cancer	3.38e-05	0.000554	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—NDUFA12—bone cancer	3.37e-05	0.000553	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.36e-05	0.00055	CbGpPWpGaD
Mifepristone—ABCC1—Disease—TGFBR2—bone cancer	3.35e-05	0.000549	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CYP3A4—bone cancer	3.28e-05	0.000538	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.27e-05	0.000535	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—GNA11—bone cancer	3.16e-05	0.000517	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CYP3A4—bone cancer	2.86e-05	0.000469	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—GSTP1—bone cancer	2.81e-05	0.00046	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—NT5C3A—bone cancer	2.79e-05	0.000458	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.64e-05	0.000432	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—ENO2—bone cancer	2.63e-05	0.000431	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—KIT—bone cancer	2.45e-05	0.000402	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—GSTP1—bone cancer	2.45e-05	0.000401	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—DHFR—bone cancer	2.44e-05	0.0004	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—BRAF—bone cancer	2.31e-05	0.000378	CbGpPWpGaD
Mifepristone—ABCC1—Disease—KIT—bone cancer	2.29e-05	0.000375	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—GNA11—bone cancer	2.28e-05	0.000374	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.21e-05	0.000363	CbGpPWpGaD
Mifepristone—ABCC1—Disease—BRAF—bone cancer	2.15e-05	0.000352	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CYP3A4—bone cancer	2.07e-05	0.000339	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—ENO2—bone cancer	1.99e-05	0.000326	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—MDM2—bone cancer	1.93e-05	0.000317	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—ENO2—bone cancer	1.87e-05	0.000307	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—DHFR—bone cancer	1.84e-05	0.000302	CbGpPWpGaD
Mifepristone—ABCC1—Disease—MDM2—bone cancer	1.8e-05	0.000295	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—GSTP1—bone cancer	1.77e-05	0.00029	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—DHFR—bone cancer	1.74e-05	0.000285	CbGpPWpGaD
Mifepristone—ABCC1—Disease—PTGS2—bone cancer	1.74e-05	0.000285	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GNA11—bone cancer	1.72e-05	0.000282	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—JUN—bone cancer	1.68e-05	0.000275	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—MMP9—bone cancer	1.63e-05	0.000268	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GNA11—bone cancer	1.62e-05	0.000266	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CYP3A4—bone cancer	1.56e-05	0.000256	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CYP3A4—bone cancer	1.47e-05	0.000241	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—PTGS2—bone cancer	1.45e-05	0.000238	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GSTP1—bone cancer	1.34e-05	0.000219	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—EGFR—bone cancer	1.32e-05	0.000216	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—PTGS2—bone cancer	1.27e-05	0.000208	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GSTP1—bone cancer	1.26e-05	0.000206	CbGpPWpGaD
Mifepristone—ABCC1—Disease—EGFR—bone cancer	1.23e-05	0.000202	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—ENO2—bone cancer	1.22e-05	0.000201	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—DHFR—bone cancer	1.14e-05	0.000186	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TP53—bone cancer	1.11e-05	0.000182	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GNA11—bone cancer	1.06e-05	0.000174	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—PTGS2—bone cancer	9.17e-06	0.00015	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GSTP1—bone cancer	8.23e-06	0.000135	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—PTGS2—bone cancer	6.92e-06	0.000113	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—PTGS2—bone cancer	6.52e-06	0.000107	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—PTGS2—bone cancer	4.26e-06	6.98e-05	CbGpPWpGaD
